

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

- 1-6 (Cancelled)
7. (Currently amended) A method for treating metabolic bone disease, said method comprising modulating PEX expression or activity wherein such modulation results in modulation of PTH and/or PTHrP levels that regulate osteoblast activity in a patient to modulate bone breakdown and/or bone formation.
8. (Currently amended) The method of claim 8, wherein said metabolic bone diseases is selected from the group consisting of osteomalacia, osteoporosis, osteopetrosis, Paget's disease ~~or~~ and X-linked hypophosphatemic rickets.
9. (Currently amended) ~~Use of a compound~~ A method for the modulation of PTH and PTHrP levels that regulate osteoblast activity in the treatment of metabolic bone disease, comprising administering to a subject having a metabolic bone disease a compound that modulates PEX expression or activity.
10. (Currently amended) The ~~use~~ method of claim 9, wherein said metabolic bone disease is selected from the group consisting of osteomalacia, osteoporosis, osteopetrosis, Paget's disease ~~or~~ and X-linked hypophosphatemic rickets.
- 11-19 (Cancelled)

20. (New) A method for treating metabolic bone disease, said method comprising modulating PTH and/or PTHrP by administering PEX.
21. (New) The method of claim 20, wherein PEX modulates PTH and/or PTHrP levels to modulate bone breakdown and/or bone formation.
22. (New) The method of claim 20, wherein said metabolic bone disease is selected from the group consisting of osteomalacia, osteoporosis, osteopetrosis, Paget's disease and X-linked hypophosphatemic rickets.
23. (New) A method for the modulation of PTH and/or PTHrP levels comprising the administration of PEX or a modulator of PEX expression or activity.
24. (New) The method of claim 23, wherein modulation of PTH and/or PTHrP levels is used for the treatment of metabolic bone disease.
25. (New) The use of claim 24, wherein said metabolic bone disease is selected from the group consisting of osteomalacia, osteoporosis, osteopetrosis, Paget's disease and X-linked hypophosphatemic rickets.
26. (New) A method for modulating PTH and/or PTHrP levels comprising administering PEX, or functional equivalent thereof.
27. (New) A method for modulating PEX enzymatic activity comprising administering a PEX-binding compound.
28. (New) The method of claim 27, wherein said PEX-binding compound modulates PEX activity to modulate PTH and/or PTHrP levels.